The -844C/T polymorphism in the Fas ligand promoter associates with Taiwanese SLE

Genes and Immunity

Volumn 6, Issue 2, 2005, Pages 123-128

  Chen, J Y ^a   Wang, C M ^a   Ma, C C ^a   Chow, Y H ^a   Luo, S F ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Fas ligand; NF B; Polymorphism; Systemic lupus erythematosus

Indexed keywords

ADENINE; CCAAT ENHANCER BINDING PROTEIN BETA; CYTOSINE; FAS ANTIGEN; FAS LIGAND; GENOMIC DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TYROSINE;

ADULT; AFRICAN AMERICAN; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BINDING SITE; CAUCASIAN; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE ACTIVATION; GENE LOCATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PATHOGENESIS; POPULATION GENETICS; PRIORITY JOURNAL; PROMOTER REGION; RACE DIFFERENCE; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TAIWAN;

ASIAN CONTINENTAL ANCESTRY GROUP; FAS LIGAND PROTEIN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEMBRANE GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS (GENETICS); TAIWAN;

EID: 15944383034     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6364158     Document Type: Article

References (45)

1. Horwitz DA, Stohl W, Gray JD. T lymphocytes, natural killer cells and immune regulation. In: Wallace DJ, Hann BH (eds). In Dubois' Lupus Erythematosus. Lippincott Willams & Wilkins: Philadelphia, Pennsylvania, 2001, pp 155-185.
2. Strasser A, O'Connor L, Dixit VM et al. Apoptosis signaling. Annu Rev Biochem 2000; 69: 217-245.
3. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erthematosus. J Immunol 1994; 152: 3685-3692.
4. Silvestris F, Grinello D, Tucci M, Cafforio P, Dammacco F. Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-1) in active lupus. Lupus 2003; 12: 8-14.
5. Grondal G, Traustadottir KH, Kristjansdottir H et al. Increased T-lymphocyte apoptosis/necrosis and IL-10 producing cells in patients and their spouses in Icelandic systemic lupus erythematosus multicase families. Lupus 2002; 11: 435-442,
6. Courtney PA, Crockard AD, Williamson K, Irvine AE, Kennedy RJ, Bell AL. Increased apoptotic peripheral blood neutrophils in systemic lupus erthematosus: relations with disease activity, antibodies to double stranded DNA, and neutrophia. Ann Rheum Dis 1999; 58: 309-314.
7. McConnell JR, Crockard AD, Cairns AP, Bell AL. Neutrophils from systemic lupus erythematosus patients demonstrate increased nuclear DNA damage. Clin Exp Rheumatol 2002; 20: 653-660.
8. Perniok A, Wedekind F, Heremann M, Specker C, Schneider M. High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erthematosus. Lupus 1998; 7: 113-118.
9. Ren Y, Tang J, Mok MY, Chan AW, Wu A, Lau CS. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2888-2897.
10. Shoshan Y, Shapira I, Toubi E, Frolkis I, Yaron M, Mevorach D. Accelerated Fas-mediated apoptosis of monocytes and maturing macrophages from patients with systemic lupus erythematosus: relevance to in vitro impairment of interaction with iC3b-opsonized apoptotic cells. J Immunol 2001; 167: 5963-5969.
11. Cairns AP, Crockard AD, McConnell JR, Courtney PA, Bell AL. Reduced expression of CD44 on monocytes and neutrophils in systemic lupus erythematosus: relations with apoptotic neutrophils and disease activity. Ann Rheum Dis 2001; 60: 950-955.
12. Herrmann M, Voll RE, Zoller OM, Hagenhoferr M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cells material by monocytes-derived macrophages from patients with systemic lupus erthematosus. Arthritis Rheum 1998; 41: 1241-1250.
13. Lee HO, Ferguson TA. Biology of FasL. Cytokine Growth Factor Rev 2003; 14: 325-335.
14. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991; 9: 243-269.
15. Takahashi T, Tanaka M, Brannan CI et al. Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell 1994; 76: 969-976.
16. Rieux-Laucat F, Fischer A, Deist FL. Cell-death signaling and human disease. Curr Opin Immunol 2003; 15: 325-331.
17. Wang J, Zheng L, Lobito A et al. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 1999; 98: 47-58.
18. Drappa J, Vanishnaw AK, Sullivan KE, Chu JL, Elkon KB. The Canale Smith syndrome: an inherited autoimmune disorder associated with defective lympocyte apoptosis and mutations in the Fas gene. N Engl J Med 1996; 335: 1643-1649.
19. Vaishnaw AK, Toubi E, Ohsko S et al. The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erthematosus, in human CD95 (Fas/APO-1) mutations. Arthritis Rheum 1999; 42: 1833-1842.
20. Kovacs B, Liossis SN, Dennis GJ, Tsokos GC. Increased expression of functional Fas-ligand in activated T cells from patients with systemic lupus erythematosus. Autoimmunity 1997; 25: 213-221.
21. McNally J, Yoo DH, Drappa J et al. Fas ligand expression and function in systemic lupus erythematosus. J Immunol 1997; 159: 4628-4636.
22. Eneslatt K, Rantapaa-Dahlqvist S, Uddhammar A, Sundqvist KG. The regulation of FasL expression - a distinguishing feature between monocytes and T lymphocytes/NK cells with possible implications for SLE. J Clin Immunol 2001; 21: 183-192.
23. Suzuki N, Ichino M, Mihara S, Kaneko S, Sakane T. Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41: 344-353.
24. Sakata K, Sakata A, Vela-Roch N et al. Fas (CD95)-transduced signal preferentially stimulates lupus peripheral T lymphocytes. Eur J Immunol 1998; 28: 2648-2660.
25. Courtney PA, Crockard AD, Williamson K, McConnell J, Kennedy RJ, Bell AL. Lymphocyte apoptosis in systemic lupus erythematosus: relationships with Fas expression, serum soluble Fas and disease activity. Lupus 1999; 8: 508-513.
26. Al-Maini MH, Mountz JD, Al-Mohri HA et al. Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erthematosus. Lupus 2000; 9: 132-139.
27. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erthematosus and lymphoproliferative disease. J Clin Invest 1996; 98: 1107-1113.
28. Kojima T, Horiuchi T, Nishizaka H et al. Analysis of Fas ligand gene mutation in patients with systemic lupus erthematosus. Arthritis Rheum 2000; 43: 135-139.
29. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S. Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 1994; 6: 1567-1574.
30. Li-Weber M, Krammer PH. Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin Immunol 2003; 15 145-157.
31. Wu J, Metz C, Xu X et al. A novel polymorphic CAAT/ enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003; 170: 132-138.
32. White S, Rosen A. Apoptosis in systemic lupus erythematosus. Curr Opin Rheumatol 2003; 15: 557-562.
33. Salmon M, Gordon C. The role of apoptosis in systemic lupus erthematosus. Rheumatology 1999; 38: 1177-1183.
34. Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmumity. Nat Immunol 2000; 1: 469-474.
35. Huizinga TW, Pisetsky DS, Kimberly RP. Associations, populations, and the truth: recommendations for genetic association studies in arthritis & rheumatism. Arthritis Rheum 2004; 50: 2066-2071.
36. Stuck BJ, Pani MA, Besrour F et al. No association of two Fas gene polymorphisms with Hashimoto's thyroiditis and Graves' disease. Eur J Endocrinol 2003; 149: 393-396.
37. Stuck BJ, Pani MA, Besrour F et al. Fas ligand gene polymorphisms are not associated with Hashimoto's thyroiditis and Graves' disease. Hum Immunol 2003; 64: 285-289.
38. Nolsoe RL, Kristiansen OP, Larsen ZM, johannesen J, Pociot F, Mandrup-Poulsen T. Complete mutation scan of the human Fas ligand gene: linkage studies in Type I diabetes mellitus families. Diabetologia 2002; 45: 134-139.
39. Matsui K, Omura S, Cui H, Schauer SL, Sonenshein GE, Ju ST. Proteasome regulation of Fas ligand cytotoxicity. Eur J Immunol 1997; 27: 2269-2278.
40. Cui H, Matsui K, Omura S et al. Proteasome regulation of activation-induced T cell death. Proc Natl Acad Sci USA 1997; 94: 7515-7520.
41. Hsu SC, Gavrilin MA, Lee HH, Wu CC, Han SH, Lai MZ. NF-kappa B-dependent Fas ligand expression. Eur J Immunol 1999; 29: 2948-2956.
42. Holtz-Heppelmann CJ, Algeciras A, Badley AD, Paya CV. Transcriptional regulation of the human FasL promoter-enhancer region. J Biol Chem 1998; 273: 4416-4423.
43. Li-Weber M, Laur O, Dern K, Krammer PH. T cell activation-induced and HIV tat-enhanced CD95(APO-1/Fas) ligand transcription involves NF-kappaB. Eur J Immunol 2000; 30: 661-670.
44. Kasibhatla S, Genestier L, Green DR. Regulation of fasligand expression during activation-induced cell death in T lymphocytes via nuclear factor kappaB. J Biol Chem 1999; 274: 987-992.
45. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1998; 1: 543-551.